receive daily
reports of the
TOP PICKS
OR
your personal
stock choices
| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
|
| There are 6 registered members and 93 guests viewing the site. | Follow us on Twitter |  Rss Top Picks Feed | Rss Daily Feed |
|
| PAST TOP PICK | 1.660 | Benj Gallander | (Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt. | 2011-12-06 | |
| PAST TOP PICK | 1.600 | Benj Gallander | (A Top Pick Nov 11/10. Up 28.57%.) | 2011-11-03 | |
| PAST TOP PICK | 1.250 | Benj Gallander | (Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list. | 2011-10-04 | |
| TOP PICK | 1.300 | Benj Gallander | Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet. | 2010-11-11 | |
| TOP PICK | 3.710 | Benj Gallander | Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet. | 2007-12-24 | |
| WEAK BUY | 3.070 | Benj Gallander | Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management. | 2006-10-06 | |
| PAST TOP PICK | 3.480 | Benj Gallander | (A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list. | 2006-01-30 | |
| TOP PICK | 3.150 | Ben Stadelmann | In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field. | 2005-09-06 | |
| TOP PICK | 3.970 | Ben Stadelmann | They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help. | 2005-01-12 | |
| PAST TOP PICK | 3.900 | Benj Gallander | (A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management. | 2004-11-09 | |
| TOP PICK | 3.740 | Ben Stadelmann | A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments. | 2004-09-16 | |
| TOP PICK | 4.360 | Benj Gallander | 2004-07-21 | ||
| TOP PICK | 4.370 | Benj Gallander | Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt. | 2004-07-16 |
